Alzinova Ab · OMXSTO:ALZ
Alzinova Ab — Investor Presentation (February 2022)
25 slides from Alzinova Ab's investor presentation, Feb 28, 2022
Slide 1: Company presentation
alzinova Company presentation
Slide 2: Forward looking statements
Forward looking statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate
Slide 3: Imagine if there was a vaccine against Alzheimer's disease
Imagine if there was a 3 vaccine against Alzheimer's disease
Slide 4: Alzinova is developing the first oligomer-specific vaccine against Alzheimer's disease
Alzinova is developing the first oligomer-specific vaccine against Alzheimer’s disease Swedish biopharma company Based in Gothenburg. Founded: 2011 High unmet medical need for Alzheimer’s disease Innovative science and proprietary technology enables development of disease-modifying treatments for Al
Slide 5: Alzheimer's disease is a progressively debilitating disease with a huge unmet medical need
Alzheimer’s disease is a progressively debilitating disease with a huge unmet medical need >55 million people have dementia, >150 million in 2050. (Alzheimer’s = 60-80% of all dementia) Impacts quality of life for patients, their families and care givers Annual cost of dementia US $1.3 trillion (US
Slide 6: Enormous market potential. Blockbuster status predicted for Alzheimer's treatments by 2026
Enormous market potential. “Blockbuster status” predicted for Alzheimer’s treatments by 2026 Alzheimer’s therapeutics market = US $13 billion by 2028 Sales and revenue potential of a new drug is substantial Two of 7 predicted blockbusters by 2026 are new anti- Alzheimer’s drugs with US $1.7 - 4.5 bi
Slide 7: Vaccines: Best-in-class potential
Best-in-class potential. Creates strong position for Alzinova to take market share in a growing market Non-specific binding Non-specific binding Specific binding Selectivity for aggregated Aβ Oligomer-specific targeting Aβ40 Aβ42 Toxic forms (oligomers) Insoluble Aβ forms (fibrils) Side effects (ARI
Slide 8: Alzinova's AβCC peptide technology targeting neurotoxic oligomers
Alzinova’s AβCC peptide™ technology enables development of high precision, disease-modifying therapies specifically targeting the neurotoxic oligomers Aβ – amyloid-beta 8 ©2022 Alzinova AB (publ), All rights reserved
Slide 9: Alzinova's AβCC peptide technology targeting neurotoxic oligomers
Alzinova’s AβCC peptide™ technology enables development of high precision, disease-modifying therapies specifically targeting the neurotoxic oligomers Aβ – amyloid-beta 9 ©2022 Alzinova AB (publ), All rights reserved
Slide 10: Alzinova is developing two oligomer-specific products based on the same technology
Alzinova is developing two oligomer-specific products based on the same proprietary technology • Highly specific disease modifying therapeutics, directed towards the neurotoxic oligomeric amyloid beta • Opportunity to become an effective and well tolerated treatment to halt and prevent Alzheimer’s •
Slide 11: ALZ-101 and ALZ-201 represent a potential breakthrough in Alzheimer's Disease
ALZ-101 and ALZ-201 represent a potential breakthrough in Alzheimer's Disease • ALZ-101 vaccine • ALZ-201 monoclonal antibody − High patient compliance (few booster doses) − Accurate antibody dosing − Long-acting − Lower doses (vs. non-specific antibody) − Preventive treatment possible − Well tolera
Slide 12: Alzinova's product pipeline offers complementary ways to fight Alzheimer's Disease
Alzinova's product pipeline offers complementary ways to fight Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Planned Milestone ALZ-1011) therapeutic H2 2023 Topline data vaccine clinical phase 1b ALZ-2012) monoclonal H1 2022 Decision on way antibody forward New innovati
Slide 13: ALZ-101 is differentiated from other immunotherapies
ALZ-101 is differentiated from other immunotherapies developed against Alzheimer's Disease • Highly specific therapeutic vaccine, directed towards the neurotoxic oligomeric Aβ • Opportunity to become an effective and well tolerated treatment to halt and prevent Alzheimer’s • Long-acting and cost-eff
Slide 14: Strong data supports clinical development of ALZ-101
Strong data supports clinical development of ALZ-101 Transgenic mice vaccinated with ALZ-101 • Comprehensive pre-clinical package showed a 25% increase of synapse density compared to controls – ALZ-101 is well tolerated in non-clinical safety and toxicity studies (monkeys and rabbits) ✓ – Efficacy d
Slide 15: ALZ-101 Phase 1b clinical study in patients with Alzheimer's disease
ALZ-101 Phase 1b clinical study in patients with Alzheimer’s disease 20-week study with four doses of ALZ-101/placebo on week 0, 4, 8 and 16 with follow-up period of 48 weeks ALZ-101 Endpoints: 125 μg N=10 Primary: safety, tolerability ALZ-101 Secondary: Immunogenicity 26 subjects R (Aβ-specific) wi
Slide 16: ALZ-201 monoclonal antibody is different from known antibodies
ALZ-201 monoclonal antibody is different from known antibodies • ALZ-201 has a binding profile that differs from known antibodies • Targets a very small fraction of all Aβ with a profound effect on the neurotoxic oligomeric Aβ • The toxic form of Aβ is very low in brain and high selectivity is likel
Slide 17: ALZ-201 in the portfolio of disease-modifying therapies against Alzheimer's disease
ALZ-201 in the portfolio of disease-modifying therapies against Alzheimer’s disease. • ALZ-201, a monoclonal antibody, differentiated from other immunotherapies developed against Alzheimer’s − Highly specific, directed towards the neurotoxic oligomeric Aβ − Opportunity to become an effective and wel
Slide 18: Development of ALZ-101 and ALZ-201 - a three-pronged approach
Development of vaccine ALZ-101 and monoclonal antibody ALZ-201 - a three-pronged approach ALZ-101 vaccine - phase 1b study • 1 year recruitment – ongoing ALZ-101 vaccine – phase 2 ready • Long-term extension study of phase 1b – planning • Process optimization of manufacturing of peptide (ALZ-101) –
Slide 19: Alzinova's business model: develop, document, prepare, partner
Alzinova's business model: develop, document, prepare, partner • Develop novel disease-modifying immunotherapies based on proprietary AβCC technology • Document safety and tolerability in patients with Alzheimer’s disease • Prepare (in parallel) for phase 2 to optimize the value of the candidates •
Slide 20: Experienced management team and innovation-focused collaborations
Experienced management team and innovation-focused collaborations Kristina Torfgård, PhD Anders Sandberg, PhD Anders Bylock, MD, PhD Chief Executive Officer Chief Scientific Officer and Chief Medical Officer Co-Founder >25 years experience – >30 years experience – AstraZeneca, Albireo >20 years expe
Slide 21: Board of Directors with extensive pharma and biopharma experience
Board of Directors with extensive pharma and biopharma experience Björn Larsson Anders Blom Per-Göran Gillberg, PhD Chair of the Board >25 years experience – 35 years in experience – >25 years experience – Pharmacia & Upjohn, Q-Med AB, Kabi, Kabi Pharmacia, Pharmacia & Novo Nordisk, AstraZeneca, Nex
Slide 22: Capitalisation table, summary of shares and options
Capitalisation table, summary of shares and options Shareholders, as per 30 December 2021: Capitalization table (amounts in million SEK): Market cap, as per 25 Feb. 2022 93.7 Subscription warrants TO2 2020/2022 2.) 2.8 Share options incentive program 2020/2023 (SEK 22,50 WAEP) 3.3 Total, including f
Slide 23: Financial information
Financial information amounts in thousand SEK Income statement Balance sheet Oct-Dec 2021 Oct-Dec 2020 Jan-Dec 2021 Jan-Dec 2020 31 Dec '21 31 Dec '20 Net sales - - - - ASSETS Fixed assets Own work capitalized 2,723 3,630 17,322 14,898 Intangible assets 2,723 3,630 17,332 14,898 Capitalized expendit
Slide 24: Summary: Alzinova's portfolio offers a potential breakthrough for Alzheimer's patients
Summary: Alzinova’s portfolio offers a potential breakthrough for the treatment of Alzheimer’s patients High unmet medical need for disease-modifying treatments of Alzheimer’s disease • Short-term goal: First oligomer-specific clinical trial with a therapeutic vaccine in patients by Q3 2021✓ • Mid-t
Slide 25: Thank you!
alzinova® Thank you!